POHMS wants to thank our corporate sponsors. With your support we are able to fulfill the mission of this organization which is to improve the business conditions of the hematology oncology practice.
Please see information below for 2018 Corporate Sponsorship:
Amgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s lives.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.
Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease.
At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer.As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
CHOC was established to function as a group purchasing organization for POHMS members and to share any benefits derived from group purchasing activities.
CHOC selects a preferred vendor, based on a competitive bid process, to provide aggressive drug pricing, payment terms and a variety of related services eligible to CHOC member practices. CHOC's current preferred vendor is McKesson Specialty Health.
CHOC believes every practice has full control over their ability to buy whatever drugs they choose. CHOC’s goal is to assist members with making well-informed decisions at the best available price.
CHOC's vision is to provide an optimal drug-purchasing environment for Hematology Oncology practices.
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for almost 30 years, using human genetic information to discover, develop, commercialize and manufacture biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and over 40 projects in the pipeline. The company is the leading provider of anti-tumor therapeutics in theUnited States. With its strength in all areas of the drug development process — from research and development to manufacturing and commercialization — Genentech continues to transform innovative science into breakthrough therapies for patients. For more general information about the company, visit our corporate overview section.
Lilly is a pioneer in chemotherapy drugs, having introduced vincristine and vinblastine in the 1960s. These anticancer drugs, known as vinca alkaloids, were derived from the rosy periwinkle plant. In 1996, Lilly leveraged this expertise with the introduction of GEMZAR® (gemcitabine HCl for injection) for the treatment of non-small cell lung cancer, pancreatic cancer, and metastatic breast cancer.
McKesson Specialty Health empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our community oncology practice customers and help them provide quality care for patients.
Oncology Supply is the nation’s largest distributor of Chemotherapy drugs & Supplies, earning a respected name in the wholesale specialty arena with more than 30 years of experience. For the community-based oncology practice, Oncology Supply has become the first choice for reliability, stability, integrity and honesty. Bringing technology to the forefront, Oncology Supply’s Nucleus® cabinet offers support and solutions for your practice’s inventory management needs. Our goal is to deliver responsive and innovative solutions to help our business partners positively impact cancer patients’ lives. For more information, visit www.oncologysupply.com.
TAKEDA ONCOLOGY (formerly known as MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY) endeavors to deliver novel medicines to cancer patients worldwide through our science, innovation and passion for improving patients’ lives. We know this mission is not an easy one but we are up to the task: we aspire to cure cancer.
Array Biopharma Inc
Astellas Pharma US INC
For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease.
Built upon a rich legacy of innovative "firsts" Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology and nephrology. With the same unwavering passion for new challenges, we dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.
Rooted in rich scientific collaborations and community-based relationships, we have access to some of the top minds in science today, allowing us to advance the treatment of patients through our innovative medicines. Our discoveries lead us not only to new treatments, but also to new ways to empower patients and expand their access to quality care – because we believe that changing lives for the better takes more than medicine.
Sanofi's focus on patients has driven our historical and ongoing strategy to create long-term value by researching and delivering the best treatments. Sanofi’s oncology heritage has given us an extensive knowledge base that enriches our current research expertise. This experience encompasses a wide variety of cancer types, disease stages, patient populations, and patient needs. As a global healthcare company focused on patient needs, we are committed to attacking cancer on all fronts.
Taiho Oncology Inc
None at this time.
Sponsors & Exhibitors
Bayer HealthCare Pharmaceuticals, Inc.
At Bayer our mission is Science For A Better Life. Bayer HealthCare discovers and manufactures innovative products that will improve human health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease.
Boehringer Ingelheim Oncology
In the first quarter of 2008, Eisai, Inc. purchased MGI Pharma. Eisai Inc. (pronounced â-zî) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ending March 31, 2007).
Headquartered in Woodcliff Lake, New Jersey, we are dedicated to a tradition of genuine concern for people and are driven by the desire to meet the diverse health care needs of patients and their families and caregivers. We are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd.., which has a strong and lasting commitment to the U.S. market.
Genoptix Medical Laboratory
Onco 360, Oncology Pharmacy
Pfizer Oncology Patient Assistance